Get the latest news, insights, and market updates on CPRX (Catalyst Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, Dec Nov 18, 2025 - $CPRX
Is Catalyst Pharmaceuticals Still a Bargain After Pipeline Expansion and 8% Weekly Gain?
Wondering if Catalyst Pharmaceuticals is a hidden gem or priced to perfection? You're not alone, and today we're digging into what the market really thinks this stock is worth. Catalyst's share price has climbed 8.4% over the last week and is up 12.5% over the past year, hinting at both growing optimism and a shift in the way investors are weighing its potential. Recent news of an expanded product pipeline and positive updates in regulatory proceedings have been fueling... Nov 15, 2025 - $CPRX
Wall Street Analysts Believe Catalyst (CPRX) Could Rally 51.45%: Here's is How to Trade
The consensus price target hints at a 51.5% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Nov 13, 2025 - $CPRX
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Nov 13, 2025 - $CPRX
Is Catalyst Pharmaceuticals’ (CPRX) Upgraded Revenue Forecast Signaling a Shift in Growth Prospects?
Catalyst Pharmaceuticals raised its full-year 2025 revenue guidance to between US$565 million and US$585 million after reporting third quarter results, which included revenue of US$148.39 million and net income of US$52.78 million, both up from the prior year. The company also received recognition on BioSpace’s 2026 Best Places to Work list and highlighted increased momentum from its key products and patient access initiatives. We’ll explore how Catalyst’s revenue guidance increase, grounded... Nov 7, 2025 - $CPRX
Catalyst: Q3 Earnings Snapshot
CORAL GABLES, Fla. AP) — Catalyst Pharmaceutical Partners Inc. CPRX) on Wednesday reported third-quarter profit of $52.8 million. Nov 5, 2025 - $CPRX
Santhera Closes USD 13 Million Royalty Monetization Agreement
Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® (vamorolone). The agreement was initially secured in September 2025 with R-Bridge, an affiliate of CBC Group, covering 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals, Inc. in North America and Sperogenix Therapeutics Ltd in China. Since initially securin Nov 5, 2025 - $CPRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple